E Pourcher - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

E Pourcher

Showing results (21-30 of 23) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 23 results.

Pharmacotherapy|December 28, 1999

CYP2D6 mutations and therapeutic outcome in schizophrenic patientsB A Hamelin, P G Dorson, D Pabis, et al.

Movement Disorders : Official Journal of the Movement Disorder Society|January 1, 1989

Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's diseaseJ A Temlett, N P Quinn, P G Jenner, et al.

Journal of Clinical Psychopharmacology|June 1, 2000

Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study GroupR H Bouchard, C Mérette, E Pourcher, et al.

Pageof 3

Search research articles

Showing results (21-30 of 23) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 23 results.

Pharmacotherapy|December 28, 1999

CYP2D6 mutations and therapeutic outcome in schizophrenic patientsB A Hamelin, P G Dorson, D Pabis, et al.

Movement Disorders : Official Journal of the Movement Disorder Society|January 1, 1989

Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's diseaseJ A Temlett, N P Quinn, P G Jenner, et al.

Journal of Clinical Psychopharmacology|June 1, 2000

Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study GroupR H Bouchard, C Mérette, E Pourcher, et al.

Pageof 3